Cargando…
Endogenous incretin levels and risk of first incident cancer: a prospective cohort study
Concerns have been raised regarding a potentially increased risk of cancer associated with treatment with glucagon-like peptide-1 (GLP-1) receptor agonists. Here, we explored whether fasting and oral glucose tolerance test post-challenge glucose-dependent insulinotropic peptide (GIP) and GLP-1 level...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825393/ https://www.ncbi.nlm.nih.gov/pubmed/36611045 http://dx.doi.org/10.1038/s41598-023-27509-3 |
_version_ | 1784866621050847232 |
---|---|
author | Jujić, Amra Godina, Christopher Belting, Mattias Melander, Olle Juul Holst, Jens Ahlqvist, Emma Gomez, Maria F. Nilsson, Peter M. Jernström, Helena Magnusson, Martin |
author_facet | Jujić, Amra Godina, Christopher Belting, Mattias Melander, Olle Juul Holst, Jens Ahlqvist, Emma Gomez, Maria F. Nilsson, Peter M. Jernström, Helena Magnusson, Martin |
author_sort | Jujić, Amra |
collection | PubMed |
description | Concerns have been raised regarding a potentially increased risk of cancer associated with treatment with glucagon-like peptide-1 (GLP-1) receptor agonists. Here, we explored whether fasting and oral glucose tolerance test post-challenge glucose-dependent insulinotropic peptide (GIP) and GLP-1 levels were associated with incident first cancer. Within the cardiovascular re-examination arm of the population-based Malmö Diet Cancer study (n = 3734), 685 participants with a previous cancer diagnosis were excluded, resulting in 3049 participants (mean age 72.2 ± 5.6 years, 59.5% women), of whom 485 were diagnosed with incident first cancer (median follow-up time 9.9 years). Multivariable Cox-regression and competing risk regression (death as competing risk) were used to explore associations between incretin levels and incident first cancer. Higher levels of fasting GLP-1 (462 incident first cancer cases/2417 controls) showed lower risk of incident first cancer in competing risk regression (sub-hazard ratio 0.90; 95% confidence interval 0.82–0.99; p = 0.022). No association was seen for fasting GIP, post-challenge GIP, or post-challenge GLP-1 and incident first cancer. In this prospective study, none of the fasting and post-challenge levels of GIP and GLP-1 were associated with higher risk of incident first cancer; by contrast, higher levels of fasting GLP-1 were associated with lower risk of incident first cancer. |
format | Online Article Text |
id | pubmed-9825393 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-98253932023-01-09 Endogenous incretin levels and risk of first incident cancer: a prospective cohort study Jujić, Amra Godina, Christopher Belting, Mattias Melander, Olle Juul Holst, Jens Ahlqvist, Emma Gomez, Maria F. Nilsson, Peter M. Jernström, Helena Magnusson, Martin Sci Rep Article Concerns have been raised regarding a potentially increased risk of cancer associated with treatment with glucagon-like peptide-1 (GLP-1) receptor agonists. Here, we explored whether fasting and oral glucose tolerance test post-challenge glucose-dependent insulinotropic peptide (GIP) and GLP-1 levels were associated with incident first cancer. Within the cardiovascular re-examination arm of the population-based Malmö Diet Cancer study (n = 3734), 685 participants with a previous cancer diagnosis were excluded, resulting in 3049 participants (mean age 72.2 ± 5.6 years, 59.5% women), of whom 485 were diagnosed with incident first cancer (median follow-up time 9.9 years). Multivariable Cox-regression and competing risk regression (death as competing risk) were used to explore associations between incretin levels and incident first cancer. Higher levels of fasting GLP-1 (462 incident first cancer cases/2417 controls) showed lower risk of incident first cancer in competing risk regression (sub-hazard ratio 0.90; 95% confidence interval 0.82–0.99; p = 0.022). No association was seen for fasting GIP, post-challenge GIP, or post-challenge GLP-1 and incident first cancer. In this prospective study, none of the fasting and post-challenge levels of GIP and GLP-1 were associated with higher risk of incident first cancer; by contrast, higher levels of fasting GLP-1 were associated with lower risk of incident first cancer. Nature Publishing Group UK 2023-01-07 /pmc/articles/PMC9825393/ /pubmed/36611045 http://dx.doi.org/10.1038/s41598-023-27509-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Jujić, Amra Godina, Christopher Belting, Mattias Melander, Olle Juul Holst, Jens Ahlqvist, Emma Gomez, Maria F. Nilsson, Peter M. Jernström, Helena Magnusson, Martin Endogenous incretin levels and risk of first incident cancer: a prospective cohort study |
title | Endogenous incretin levels and risk of first incident cancer: a prospective cohort study |
title_full | Endogenous incretin levels and risk of first incident cancer: a prospective cohort study |
title_fullStr | Endogenous incretin levels and risk of first incident cancer: a prospective cohort study |
title_full_unstemmed | Endogenous incretin levels and risk of first incident cancer: a prospective cohort study |
title_short | Endogenous incretin levels and risk of first incident cancer: a prospective cohort study |
title_sort | endogenous incretin levels and risk of first incident cancer: a prospective cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825393/ https://www.ncbi.nlm.nih.gov/pubmed/36611045 http://dx.doi.org/10.1038/s41598-023-27509-3 |
work_keys_str_mv | AT jujicamra endogenousincretinlevelsandriskoffirstincidentcanceraprospectivecohortstudy AT godinachristopher endogenousincretinlevelsandriskoffirstincidentcanceraprospectivecohortstudy AT beltingmattias endogenousincretinlevelsandriskoffirstincidentcanceraprospectivecohortstudy AT melanderolle endogenousincretinlevelsandriskoffirstincidentcanceraprospectivecohortstudy AT juulholstjens endogenousincretinlevelsandriskoffirstincidentcanceraprospectivecohortstudy AT ahlqvistemma endogenousincretinlevelsandriskoffirstincidentcanceraprospectivecohortstudy AT gomezmariaf endogenousincretinlevelsandriskoffirstincidentcanceraprospectivecohortstudy AT nilssonpeterm endogenousincretinlevelsandriskoffirstincidentcanceraprospectivecohortstudy AT jernstromhelena endogenousincretinlevelsandriskoffirstincidentcanceraprospectivecohortstudy AT magnussonmartin endogenousincretinlevelsandriskoffirstincidentcanceraprospectivecohortstudy |